Cellectar Biosciences will present strategic plans for 2026 at Biotech Showcase, aiming to seek conditional marketing approval from EMA for Iopofosine I 131 for WM treatment by 3Q 2026.
In accordance with advice from the European Medicines Agency's (EMA) Scientific Advice Working Party (SAWP) on Iopofosine I 131 for Waldenstrom's Macroglobulinemia (WM) treatment, a submission for Conditional Marketing Approval in Europe is anticipated in the third quarter of 2026.
Source: Unusual Whales The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments